دورية أكاديمية
أعرض في EDS

Loss of Dnmt3a increases self-renewal and resistance to pegIFN-α in JAK2-V617F-positive myeloproliferative neoplasms.

التفاصيل البيبلوغرافية
العنوان: Loss of Dnmt3a increases self-renewal and resistance to pegIFN-α in JAK2-V617F-positive myeloproliferative neoplasms.
المؤلفون: Usart M; Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland., Stetka J; Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland.; Department of Biology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic., Luque Paz D; University of Angers, Nantes Université, Centre Hospitalier Universitaire Angers, INSERM, Centre National de la Recherche Scientifique, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, Angers, France., Hansen N; Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland., Kimmerlin Q; Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland., Almeida Fonseca T; Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland., Lock M; Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland., Kubovcakova L; Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland., Karjalainen R; Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland., Hao-Shen H; Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland., Börsch A; Department of Biomedicine, Bioinformatics, University of Basel and University Hospital Basel, Basel, Switzerland.; Swiss Institute of Bioinformatics, Basel, Switzerland., El Taher A; Department of Biomedicine, Bioinformatics, University of Basel and University Hospital Basel, Basel, Switzerland.; Swiss Institute of Bioinformatics, Basel, Switzerland., Schulz J; Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland., Leroux JC; Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland., Dirnhofer S; Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland., Skoda RC; Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland.
المصدر: Blood [Blood] 2024 Jun 13; Vol. 143 (24), pp. 2490-2503.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE
أسماء مطبوعة: Publication: 2021- : [New York] : Elsevier
Original Publication: New York, Grune & Stratton [etc.]
مواضيع طبية MeSH: DNA Methyltransferase 3A*/genetics , Janus Kinase 2*/genetics , Janus Kinase 2*/metabolism , DNA (Cytosine-5-)-Methyltransferases*/genetics , DNA (Cytosine-5-)-Methyltransferases*/metabolism , Interferon-alpha*/pharmacology , Myeloproliferative Disorders*/genetics , Myeloproliferative Disorders*/pathology , Myeloproliferative Disorders*/drug therapy , Myeloproliferative Disorders*/metabolism , Drug Resistance, Neoplasm*/genetics , Hematopoietic Stem Cells*/metabolism , Hematopoietic Stem Cells*/pathology , Hematopoietic Stem Cells*/drug effects, Animals ; Mice ; Humans ; Cell Self Renewal ; Mice, Inbred C57BL ; Polyethylene Glycols/pharmacology ; Recombinant Proteins
مستخلص: Abstract: Pegylated interferon alfa (pegIFN-α) can induce molecular remissions in patients with JAK2-V617F-positive myeloproliferative neoplasms (MPNs) by targeting long-term hematopoietic stem cells (LT-HSCs). Additional somatic mutations in genes regulating LT-HSC self-renewal, such as DNMT3A, have been reported to have poorer responses to pegIFN-α. We investigated whether DNMT3A loss leads to alterations in JAK2-V617F LT-HSC functions conferring resistance to pegIFN-α treatment in a mouse model of MPN and in hematopoietic progenitors from patients with MPN. Long-term treatment with pegIFN-α normalized blood parameters and reduced splenomegaly and JAK2-V617F chimerism in single-mutant JAK2-V617F (VF) mice. However, pegIFN-α in VF;Dnmt3aΔ/Δ (VF;DmΔ/Δ) mice worsened splenomegaly and failed to reduce JAK2-V617F chimerism. Furthermore, LT-HSCs from VF;DmΔ/Δ mice compared with VF were less prone to accumulate DNA damage and exit dormancy upon pegIFN-α treatment. RNA sequencing showed that IFN-α induced stronger upregulation of inflammatory pathways in LT-HSCs from VF;DmΔ/Δ than from VF mice, indicating that the resistance of VF;DmΔ/Δ LT-HSC was not due to failure in IFN-α signaling. Transplantations of bone marrow from pegIFN-α-treated VF;DmΔ/Δ mice gave rise to more aggressive disease in secondary and tertiary recipients. Liquid cultures of hematopoietic progenitors from patients with MPN with JAK2-V617F and DNMT3A mutation showed increased percentages of JAK2-V617F-positive colonies upon IFN-α exposure, whereas in patients with JAK2-V617F alone, the percentages of JAK2-V617F-positive colonies decreased or remained unchanged. PegIFN-α combined with 5-azacytidine only partially overcame resistance in VF;DmΔ/Δ mice. However, this combination strongly decreased the JAK2-mutant allele burden in mice carrying VF mutation only, showing potential to inflict substantial damage preferentially to the JAK2-mutant clone.
(© 2024 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
References: Nat Genet. 2011 Dec 04;44(1):23-31. (PMID: 22138693)
Leukemia. 2014 Sep;28(9):1804-10. (PMID: 24549259)
Blood. 2008 Apr 15;111(8):3931-40. (PMID: 18160670)
Nature. 2004 Jun 24;429(6994):900-3. (PMID: 15215868)
Blood. 2013 Feb 14;121(7):1188-99. (PMID: 23264594)
Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2548-53. (PMID: 24550281)
Blood. 2008 Oct 15;112(8):3065-72. (PMID: 18650451)
Nat Rev Cancer. 2015 Mar;15(3):152-65. (PMID: 25693834)
Nat Cancer. 2021 May;2(5):527-544. (PMID: 35122024)
Cancer Discov. 2022 Dec 2;12(12):2763-2773. (PMID: 36169447)
Blood. 2017 Feb 9;129(6):667-679. (PMID: 28028029)
Blood. 2005 Apr 1;105(7):2724-32. (PMID: 15598809)
Nature. 2014 Aug 14;512(7513):198-202. (PMID: 25079315)
Cancer Cell. 2014 Apr 14;25(4):442-54. (PMID: 24656771)
J Exp Med. 1998 Jun 15;187(12):2009-21. (PMID: 9625760)
J Immunol Methods. 2009 Aug 15;347(1-2):70-8. (PMID: 19567251)
Blood. 2013 Aug 8;122(6):893-901. (PMID: 23782935)
Nature. 1985 Jun 20-26;315(6021):672-6. (PMID: 3925348)
Blood. 2013 May 2;121(18):3692-702. (PMID: 23487027)
N Engl J Med. 2014 Dec 25;371(26):2477-87. (PMID: 25426838)
Leukemia. 2014 Sep;28(9):1774-83. (PMID: 24699305)
J Leukoc Biol. 2002 Apr;71(4):669-76. (PMID: 11927654)
Leukemia. 2020 Apr;34(4):1075-1089. (PMID: 31732720)
Leukemia. 2022 Jul;36(7):1703-1719. (PMID: 35732831)
Cell Immunol. 2001 Dec 15;214(2):110-22. (PMID: 12088410)
Blood Adv. 2022 Apr 12;6(7):2107-2119. (PMID: 34507355)
Blood Adv. 2020 Oct 13;4(19):4887-4897. (PMID: 33035330)
Nature. 2014 Feb 20;506(7488):328-33. (PMID: 24522528)
Blood. 2013 Aug 22;122(8):1464-77. (PMID: 23863895)
N Engl J Med. 2018 Oct 11;379(15):1416-1430. (PMID: 30304655)
Stem Cell Reports. 2020 Apr 14;14(4):551-560. (PMID: 32220332)
Nat Med. 2014 Dec;20(12):1472-8. (PMID: 25326804)
Cell Rep. 2018 Apr 3;23(1):1-10. (PMID: 29617651)
Cell Stem Cell. 2021 Aug 5;28(8):1428-1442.e6. (PMID: 33743191)
Blood. 2021 Apr 22;137(16):2139-2151. (PMID: 33667305)
Nature. 2015 Apr 23;520(7548):549-52. (PMID: 25707806)
Nat Immunol. 2003 Oct;4(10):1009-15. (PMID: 14502286)
J Clin Oncol. 2018 Feb 1;36(4):310-318. (PMID: 29226763)
J Exp Med. 2021 Feb 1;218(2):. (PMID: 33075130)
Nature. 2018 Jan 11;553(7687):212-216. (PMID: 29323290)
Cancer Cell. 2010 Jun 15;17(6):584-96. (PMID: 20541703)
Blood. 2014 Apr 3;123(14):2220-8. (PMID: 24478400)
N Engl J Med. 2014 Dec 25;371(26):2488-98. (PMID: 25426837)
Cell Stem Cell. 2016 Dec 1;19(6):752-767. (PMID: 27641306)
J Clin Oncol. 2009 Nov 10;27(32):5418-24. (PMID: 19826111)
J Biol Chem. 2001 Nov 9;276(45):42462-7. (PMID: 11571274)
Genes Dev. 2004 Nov 15;18(22):2747-63. (PMID: 15545632)
Cell. 2015 Aug 27;162(5):974-86. (PMID: 26317466)
Cell. 2017 Feb 23;168(5):801-816.e13. (PMID: 28215704)
Blood. 2018 Dec 27;132(26):2707-2721. (PMID: 30366920)
المشرفين على المادة: EC 2.1.1.37 (DNA Methyltransferase 3A)
EC 2.7.10.2 (Janus Kinase 2)
EC 2.1.1.37 (DNA (Cytosine-5-)-Methyltransferases)
0 (Interferon-alpha)
0 (Dnmt3a protein, mouse)
0 (DNMT3A protein, human)
EC 2.7.10.2 (JAK2 protein, human)
Q46947FE7K (peginterferon alfa-2a)
3WJQ0SDW1A (Polyethylene Glycols)
EC 2.7.10.2 (Jak2 protein, mouse)
0 (Recombinant Proteins)
تواريخ الأحداث: Date Created: 20240317 Date Completed: 20240613 Latest Revision: 20240629
رمز التحديث: 20240629
مُعرف محوري في PubMed: PMC11208296
DOI: 10.1182/blood.2023020270
PMID: 38493481
قاعدة البيانات: MEDLINE
الوصف
تدمد:1528-0020
DOI:10.1182/blood.2023020270